The post AERO rallies 12% as capital inflows surge: Is $0.40 within reach? appeared on BitcoinEthereumNews.com. Aerodrome Finance [AERO] was the third in terms The post AERO rallies 12% as capital inflows surge: Is $0.40 within reach? appeared on BitcoinEthereumNews.com. Aerodrome Finance [AERO] was the third in terms

AERO rallies 12% as capital inflows surge: Is $0.40 within reach?

For feedback or concerns regarding this content, please contact us at [email protected]

Aerodrome Finance [AERO] was the third in terms of daily gains for the top 100 coins by capitalization. AERO rallied about 12.68%, despite its trading volume remaining relatively low, at about $18 million, per CoinMarketCap.

The rally came as Bitcoin [BTC] led the other cryptos in pushing the market higher by 6% upon surpassing $70,000. Can AERO bulls sustain this trajectory and go ahead to break past the rising trend channel?

AERO price eyes channel breakout

The 3-hour timeframe showed that the altcoin has been trading in a rising trend channel since early February. AERO had just broken above the middle level of the channel, indicating buyers were in charge.

In fact, the MACD bars were green and increasing, reinforcing buyer strength. Its signal lines had also risen above the neutral line.

The Correlation Coefficient for Aerodrome against Bitcoin was 0.84 from 0.26. This showed that the altcoin was moving simultaneously in a similar direction with BTC, which was above $70K.

Such a correlation suggests that if BTC continues to strengthen, the altcoin may as well break past the upper resistance of the channel.

Source: AERO/USDT on TradingView

Conversely, if AERO fails to stay above the mid-level between $0.35 and $0.36, it may lose its correlation to BTC. Furthermore, if BTC falls in price, it could mean the same for the altcoin.

Targets in the case of bulls continuing to buy it stood around $0.40 or higher. On the contrary, Aerodrome could fall to the $0.32 level or lower. Still, traders needed to watch these signs to confirm the continued uptrend.

Apart from its strength in the charts, whales, institutions, and retail were also bullish on AERO.

Why are both Futures and Spot markets CVD bullish?

Capital inflows recorded on-chain contributed to the bullishness.

Smart money was actively buying Base Chain tokens, with AERO leading this lot for the last 30 days with about $837.2K.

Others included TIBBIR and Virtual Protocol [VIRTUAL] at $574K and $359K, respectively, as per data from Nansen AI.

Also, retailers were buying the token, as the market cap traded at $688.48 million. For instance, a CLANKER holder bought $1.04K AERO.

Furthermore, institutions were backing a bullish outlook. After Hypersphere Capital withdrew 2.5 million AERO worth $837K from Bybit this month, AERO became its fifth-largest holding.

All this buy volume flipped the Cumulative Volume Delta to buyer-dominated on both Spot and Future market.

Source: CryptoQuant

Other Hypersphere holdings included USDC, Hyperliquid [HYPE], Worldcoin [WLD], and Maple Finance [SYRUP]. Continuation of AERO accumulation could ignite a break above the rising channel.


Final Summary

  • AERO rallied 12% amid capital inflow from smart money, retailers, and institutions.
  • AERO faces a critical test around $0.40, which was the trend channel’s upper resistance. 
Next: 38% of altcoins near all-time lows as BTC.D climbs – Setup bulls need?

Source: https://ambcrypto.com/aero-rallies-12-as-capital-inflows-surge-is-0-40-within-reach/

Market Opportunity
Aerodrome Finance Logo
Aerodrome Finance Price(AERO)
$0.3342
$0.3342$0.3342
-1.06%
USD
Aerodrome Finance (AERO) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09